News & Media
SK life science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK life science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
1/04/2021
SK Biopharmaceuticals To Sell Arvelle Therapeutics Stake As Part Of Angelini Pharma’s Acquisition Of Arvelle Therapeutics
Full release12/01/2020
SK life science Presents Latest Cenobamate Data at the American Epilepsy Society AES2020 Virtual Event
Full release10/29/2020
SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innovation
Full release10/13/2020
SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan
Full release9/11/2020
SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia
Full release7/15/2020
SK life science Expands Support for the Epilepsy Foundation to Advance Epilepsy Awareness, Research, Education and Care
Full release5/20/2020
Newly Published Study in Neurology Shows Cenobamate Significantly Reduced Seizure Frequency in Adults with Uncontrolled Partial-Onset (Focal) Seizures
Full release5/20/2020
SK life science Announces Results of Large, Open-Label Safety Study of Cenobamate Published in Epilepsia
Full release5/11/2020
SK life science Announces U.S. Availability of XCOPRI® (cenobamate tablets) CV for the Treatment of Partial-Onset Seizures in Adults
Full release5/05/2020
SK Life Science, Inc.’s Coronavirus Update
Full release